Erratum: Randomized phase 2 trial of intracoronary nitrite during acute myocardial infarction (Circulation Research (2015) 116 (437-447) DOI: 10.1161/CIRCRESAHA.116.305082);Randomized phase 2 trial of intracoronary nitrite during acute myocardial infarction

Circulation Research

Volumn 116, Issue 3, 2015, Pages 437-447

  Jones, Daniel A ^a,b   Pellaton, Cyril ^b   Velmurugan, Shanti ^a,b   Rathod, Krishnaraj Sinha ^a   Andiapen, Mervyn ^b   Antoniou, Sotiris ^a   Van Eijl, Sven ^a   Webb, Andrew J ^a   Westwood, Mark A ^b   Parmar, Mahesh K ^c   Mathur, Anthony ^a,b   Ahluwalia, Amrita ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b LONDON CHEST HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Acute myocardial infarction; Nitric oxide; Percutaneous coronary intervention

Indexed keywords

CREATINE KINASE; PLACEBO; SODIUM NITRITE; TROPONIN T;

ABSENCE OF SIDE EFFECTS; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION SIZE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MYOCARDIAL SALVAGE INDEX; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; CLINICAL TRIAL; MIDDLE AGED; MYOCARDIAL INFARCTION;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SODIUM NITRITE;

EID: 84927695357     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/RES.0000000000000051     Document Type: Erratum

References (33)

1. Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, Gitt A, Hasdai D, Hasin Y, Marrugat J, Van de Werf F, Wallentin L, Behar S; Euro Heart Survey Investigators. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J. 2006;27:2285-2293. doi: 10.1093/eurheartj/ehl196.
2. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:2155-2165. doi: 10.1056/NEJMoa0908610.
3. O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-e425.doi: 10.1161/CIR.0b013e3182742cf6.
4. Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC); Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-2619. doi: 10.1093/eurheartj/ehs215.
5. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135. doi: 10.1056/NEJMra071667.
6. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, André-Fouët X, Ovize M. Postconditioning the human heart. Circulation. 2005;112:2143-2148. doi: 10.1161/CIRCULATIONAHA.105.558122.
7. Bøtker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375:727-734. doi: 10.1016/S0140-6736(09)62001-8.
8. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473-481. doi: 10.1056/NEJMoa071142.
9. Lønborg J, Vejlstrup N, Kelbæk H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491-1499. doi: 10.1093/eurheartj/ehr309.
10. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet. 2013;381:166-175. doi: 10.1016/S0140-6736(12)60916-7.
11. Gladwin MT, Schechter AN, Kim-Shapiro DB, et al. The emerging biology of the nitrite anion. Nat Chem Biol. 2005;1:308-314. doi: 10.1038/ nchembio1105-308.
12. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012. doi: 10.1056/NEJM199312303292706.
13. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation. 2008;118:1915-1919. doi: 10.1161/CIRCULATIONAHA.108.805242.
14. Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci U S A. 2004;101:13683-13688. doi: 10.1073/pnas.0402927101.
15. Duranski MR, Greer JJ, Dejam A, Jaganmohan S, Hogg N, Langston W, Patel RP, Yet SF, Wang X, Kevil CG, Gladwin MT, Lefer DJ. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest. 2005;115:1232-1240. doi: 10.1172/JCI22493.
16. Shiva S, Sack MN, Greer JJ, Duranski M, Ringwood LA, Burwell L, Wang X, MacArthur PH, Shoja A, Raghavachari N, Calvert JW, Brookes PS, Lefer DJ, Gladwin MT. Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med. 2007;204:2089-2102. doi: 10.1084/jem.20070198.
17. Baker JE, Su J, Fu X, Hsu A, Gross GJ, Tweddell JS, Hogg N. Nitrite confers protection against myocardial infarction: role of xanthine oxidoreductase, NADPH oxidase and K(ATP) channels. J Mol Cell Cardiol. 2007;43:437-444. doi: 10.1016/j.yjmcc.2007.07.057.
18. Gonzalez FM, Shiva S, Vincent PS, Ringwood LA, Hsu LY, Hon YY, Aletras AH, Cannon RO III, Gladwin MT, Arai AE. Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. Circulation. 2008;117:2986-2994. doi: 10.1161/CIRCULATIONAHA.107.748814.
19. Jones DA, Andiapen M, Van-Eijl TJA, Webb AJ, Antoniou S, Schilling RJ, Ahluwalia A, Mathur A. The safety and efficacy of intracoronary nitrite infusion during acute myocardial infarction (nitrite-ami): Study protocol of a randomised controlled trial. BMJ Open. 2013;3
20. Cosby K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003;9:1498-1505. doi: 10.1038/nm954.
21. Dejam A, Hunter CJ, Tremonti C, Pluta RM, Hon YY, Grimes G, Partovi K, Pelletier MM, Oldfield EH, Cannon RO III, Schechter AN, Gladwin MT. Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation. 2007;116:1821-1831. doi: 10.1161/CIRCULATIONAHA.107.712133.
22. Maher AR, Milsom AB, Gunaruwan P, Abozguia K, Ahmed I, Weaver RA, Thomas P, Ashrafian H, Born GV, James PE, Frenneaux MP. Hypoxic modulation of exogenous nitrite-induced vasodilation in humans. Circulation. 2008;117:670-677. doi: 10.1161/ CIRCULATIONAHA.107.719591.
23. Velmurugan S, Kapil V, Ghosh SM, Davies S, McKnight A, Aboud Z, Khambata RS, Webb AJ, Poole A, Ahluwalia A. Antiplatelet effects of dietary nitrate in healthy volunteers: involvement of cGMP and influence of sex. Free Radic Biol Med. 2013;65:1521-1532. doi: 10.1016/j.freeradbiomed.2013.06.031.
24. Srihirun S, Sriwantana T, Unchern S, Kittikool D, Noulsri E, Pattanapanyasat K, Fucharoen S, Piknova B, Schechter AN, Sibmooh N. Platelet inhibition by nitrite is dependent on erythrocytes and deoxygenation. PLoS One. 2012;7:e30380. doi: 10.1371/journal.pone.0030380.
25. Chia S, Senatore F, Raffel OC, Lee H, Wackers FJ, Jang IK. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008;1:415-423. doi: 10.1016/j.jcin.2008.04.010.
26. Thuny F, Lairez O, Roubille F, et al. Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59:2175-2181. doi: 10.1016/j.jacc.2012.03.026.
27. Christian TF, Schwartz RS, Gibbons RJ. Determinants of infarct size in reperfusion therapy for acute myocardial infarction. Circulation. 1992;86:81-90.
28. Keeley EC, Hillis LD. Primary PCI for myocardial infarction with ST-segment elevation. N Engl J Med. 2007;356:47-54. doi: 10.1056/ NEJMct063503.
29. Armstrong PW, Westerhout CM, Welsh RC. Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. Circulation. 2009;119:1293-1303. doi: 10.1161/CIRCULATIONAHA.108.796383.
30. Siddiqi N, Neil C, Bruce M, et al.; NIAMI investigators. Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). Eur Heart J. 2014;35:1255-1262. doi: 10.1093/ eurheartj/ehu096.
31. Bøtker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375:727-734. doi: 10.1016/S0140-6736(09)62001-8.
32. Hombach V, Grebe O, Merkle N, Waldenmaier S, Höher M, Kochs M, Wöhrle J, Kestler HA. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J. 2005;26:549-557. doi: 10.1093/eurheartj/ehi147.
33. Pluta RM, Oldfield EH, Bakhtian KD, Fathi AR, Smith RK, Devroom HL, Nahavandi M, Woo S, Figg WD, Lonser RR. Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS One. 2011;6:e14504. doi: 10.1371/journal.pone.0014504.